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Human Papillomaviruses (HPV) are responsible for several diseases and some of them (such as HPV16 and HPV18) can induce cervical cancer. In this case the two HPV E6 and E7 oncoproteins are essential players in order to immortalize keratinocytes by decreasing tumor suppressor genes (p53 and pRb). Nowadays, cervical cancer is known to be the third most frequent cause of death in women and only prophylactic vaccines exist. Except classical cancer therapy (surgery and radio/chemotherapy), there is no treatment if the lesion is already developed.
Gene therapy is a promising strategy to treat cancer. We focused on RNA interference (siRNA) to target mRNA coding for both HPV oncoproteins (E6 and E7) and for an anti-apoptotic protein (MCL-1). This anti-apoptotic protein is over expressed in high grade lesion compared to low grade lesion and healthy cervix. To develop a treatment, we would like to use a transfection agent appropriate for in vivo study. siRNA would be encapsulated in lipidic nanovectors to form lipoplexes. This association is essential to protect siRNA, to allow the diffusion into the cervical mucus and to cross the anionic cellular membrane.
The aim of this study is to develop a local treatment of cervical cancer by siRNA anti-E6 and/or anti-E7 that would be encapsulated in cationic liposome.
First, we validated the efficacy of these siRNA antiE6, antiE7 and antiMCL1 with a commercially transfection agent (Oligofectamine®). Some objectives are achieved: high transfection efficiency, extinction of E6, E7 and MCL-1 mRNA, decreased proliferation and induced apoptosis of SiHa and CaSki cells. The combination of the three siRNA antiE6, antiE7 and antiMCL-1 allows a higher induction of apoptosis.

In the second step, Oligofectamine® was replaced by cationic liposomes with good physicochemical characteristics (size, surface charge, stability…). Liposomes composed of DOTAP/DOPE/Cholesterol (1:0,5:0,5 ; molar ratio) are prepared and then mixed with siRNA (100 nM; N/P 5). The size of lipoplexes is around 200nm and the zeta potential is around +45mV. This formulation leads to a very efficient transfection and the percentage of mRNA is significantly reduced. 
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